Skip to main content

Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.

Publication ,  Journal Article
Beaven, AW; Diehl, LF
Published in: Hematology Am Soc Hematol Educ Program
2015

Peripheral T-cell lymphomas (PTCL), with the exception of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), have a very poor prognosis. Although current first line chemotherapy continues to be a CHOP-like (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen there is now data suggesting that the addition of etoposide in younger patients improves outcomes. Even for those patients who do have a response to therapy, the risk of relapse remains quite high. Although autologous transplant in first remission is often used, its role as consolidation therapy in first remission remains unclear and may preferentially benefit low-risk patients. In the relapsed setting, major advances have occurred with Food and Drug Administration (FDA) approval of 4 new agents (pralatrexate, romidepsin, belinostat, brentuximab vedotin) for relapsed/refractory PTCL since 2009. These 4 drugs represent the first agents ever approved specifically for this indication. Unfortunately, with the exception of ALCL for which brentuximab vedotin will likely substantially change our approach to treatment, there are still many patients for whom available drugs will not be effective, and it is for these patients that further advances are urgently needed.

Duke Scholars

Published In

Hematology Am Soc Hematol Educ Program

DOI

EISSN

1520-4383

Publication Date

2015

Volume

2015

Start / End Page

550 / 558

Location

United States

Related Subject Headings

  • Vincristine
  • United States Food and Drug Administration
  • United States
  • Treatment Outcome
  • Risk
  • Remission Induction
  • Recurrence
  • Prognosis
  • Prednisolone
  • Oligopeptides
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beaven, A. W., & Diehl, L. F. (2015). Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematology Am Soc Hematol Educ Program, 2015, 550–558. https://doi.org/10.1182/asheducation-2015.1.550
Beaven, Anne W., and Louis F. Diehl. “Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.Hematology Am Soc Hematol Educ Program 2015 (2015): 550–58. https://doi.org/10.1182/asheducation-2015.1.550.
Beaven AW, Diehl LF. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematology Am Soc Hematol Educ Program. 2015;2015:550–8.
Beaven, Anne W., and Louis F. Diehl. “Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.Hematology Am Soc Hematol Educ Program, vol. 2015, 2015, pp. 550–58. Pubmed, doi:10.1182/asheducation-2015.1.550.
Beaven AW, Diehl LF. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematology Am Soc Hematol Educ Program. 2015;2015:550–558.

Published In

Hematology Am Soc Hematol Educ Program

DOI

EISSN

1520-4383

Publication Date

2015

Volume

2015

Start / End Page

550 / 558

Location

United States

Related Subject Headings

  • Vincristine
  • United States Food and Drug Administration
  • United States
  • Treatment Outcome
  • Risk
  • Remission Induction
  • Recurrence
  • Prognosis
  • Prednisolone
  • Oligopeptides